LIT - Leibniz Institute for Immunotherapy (former RCI)
c/o University Hospital Regensburg
www.rcii.de/en (new website coming soon!)
The long-term research interest of our lab is the immunology of allogeneic stem cell transplantation (SCT), a treatment option for patients with high-risk leukemia and lymphoma. This treatment bears the risk of graft-versus-host disease (GvHD), a severe and sometimes life-threatening complication. With our studies, we aim to develop new and improved cellular therapies to prevent or treat GvHD through the application of donor-derived CD4+CD25+Foxp3+ regulatory T cells. We are currently addressing the following research topics:
- Application of genetically engineered Treg in GvHD therapy
- Influence of the gut microbiome on donor Treg migration and function
- Immune reconstitution after allogeneic SCT
We analyse patient material and use a variety of mouse in vivo models, including germfree and gnotobiotic animals, to address our research questions. Common techniques used in the lab include high-parameter flow cytometry, retroviral-mediated gene transduction and next generation sequencing.